217 results on '"Mariette, Xavier"'
Search Results
2. Response to: Correspondence on ‘Long COVID: a new word for naming fibromyalgia?" by Mariette
3. Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis
4. Obinutuzumab in patients with Sjogren’s disease immunised against rituximab
5. Comparison between primary Sjögren’s disease patients with high or low level of dryness
6. Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
7. Efficacy of daratumumab in refractory primary Sjögren disease
8. Impact of patient ancestry on heterogeneity of Sjögren’s disease
9. Interferon signature in systemic autoimmune diseases: what does it mean?
10. Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)
11. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
12. Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
13. SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
14. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database
15. Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
16. SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
17. Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome
18. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update
19. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
20. Passive smoking in childhood and adulthood and risk of rheumatoid arthritis in women: results from the French E3N cohort study
21. Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis
22. Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
23. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
24. 2021 DORIS definition of remission in SLE: final recommendations from an international task force
25. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19
26. Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider
27. SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases
28. Lymphoma complicating rheumatoid arthritis: results from a French case–control study
29. 2021 DORIS definition of remission in SLE: final recommendations from an international task force.
30. Association between T follicular helper cells and T peripheral helper cells with B-cell biomarkers and disease activity in primary Sjögren syndrome
31. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider
32. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance
33. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
34. Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider
35. Normal salivary gland ultrasonography could rule out the diagnosis of Sjögren’s syndrome in anti-SSA-negative patients with sicca syndrome
36. Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis
37. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial
38. Response to: ‘Role of interaction between B cells and epithelial cells in pSS’ by Pringle et al
39. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
40. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020
41. Salivary gland epithelial cells from patients with Sjögren’s syndrome induce B-lymphocyte survival and activation
42. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities
43. To immunosuppress: whom, when and how? That is the question with COVID-19
44. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2
45. Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone
46. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
47. Myositis as a manifestation of SARS-CoV-2
48. Features of polymyalgia rheumatica–like syndrome after immune checkpoint inhibitor therapy
49. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
50. Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.